Is there a role of magnetic resonance imaging in deciding to stop anti-tumor necrosis factor treatment in ileal Crohn's disease?

被引：5

作者：

Gallego, Jose C. ^{[1
]}

Echarri, Ana ^{[2
]}

机构：

[1] Complexo Hosp Univ Ferrol, Radiol Dept, Av Residencia S-N, Ferrol 15405, Spain

[2] Complexo Hosp Univ Ferrol, Gastroenterol Dept, Ferrol, Spain

来源：

CLINICAL IMAGING | 2017年 / 43卷

关键词：

Crohn's disease; Magnetic resonance imaging; Anti-tumor necrosis factor agents; INFLAMMATORY-BOWEL-DISEASE; INFLIXIMAB THERAPY; CLINICAL REMISSION; FOLLOW-UP; DISCONTINUATION; MAINTENANCE; RELAPSE;

D O I：

10.1016/j.clinimag.2017.03.010

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Purpose: This study was performed to assess the ability of magnetic resonance enterography to predict the evolution of patients in whom anti-tumor necrosis factor-alpha therapy was suspended. Methods: A prospective study of patients with ileal Crohn's disease was performed. Results: Twenty-nine patients were included. Patients who later relapsed showed higher magnetic resonance scores than those who did not relapse (4.2 vs. 2.5, respectively; p < 0.02). The area under the receiving-operating characteristics curve was 0.755 when discriminating patients who relapsed. Conclusions: Magnetic resonance enterography should be taken into account when deciding the withdrawal of anti-tumor necrosis factor-alpha in patients with Crohn's disease. (C) 2017 Elsevier Inc. All rights reserved.

引用

页码：175 / 179

页数：5

共 50 条

[31] Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease
Conklin, Laurie S.
Cohen, Bernard
Wilson, Lindsay
Cuffari, Carmen
Oliva-Hemker, Maria
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (03) : 174 - 177
[32] Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn's Disease
Bafutto, Mauro
Oliveira, Enio Chaves
Rezende Filho, Joffre
GASTROENTEROLOGY RESEARCH, 2020, 13 (03) : 101 - 106
[33] Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease
Shivashankar, Raina
Pardi, Darrell S.
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2017, 46 (03) : 589 - +
[34] Anti-Tumor Necrosis Factor-Alpha (TNF-alpha) Treatment Strategies in Crohn's Disease
Reimund, Jean-Marie
Ratajczyk, Julia
Sola, Brigitte
Justum, Anne-Marie
Muller, Christian D.
RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 21 - 34
[35] Treatment of pediatric Crohn's disease (CD) with anti-tumor necrosis factor α chimeric monoclonal antibody (infliximab)
Kugathansan, S
Rivera, MT
Martinez, A
Binion, DG
Werlin, SL
GASTROENTEROLOGY, 1999, 116 (04) : A755 - A755
[36] Anti-tumor necrosis factor agents in Crohn's disease and ulcerative colitis: Beyond luminal disease
Nunez-Gomez, Laura
Mesonero-Gismero, Francisco
Albillos-Martinez, Agustin
Lopez-Sanroman, Antonio
GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41 (09): : 576 - 582
[37] The Use of Anti-Tumor Necrosis Factor Agents and Development of Psoriasis in Patients with Crohn's Disease
Lin, Ming
Blonski, Wojciech
Weiner, Mark
Tierney, Ann
Marchioni, Renee
Buchner, Anna
Lichtenstein, Gary
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S490 - S491
[38] Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease
Umeno, Junji
Matsumoto, Takayuki
Jo, Yukihiko
Ichikawa, Miki
Urabe, Kazunori
Lida, Mitsuo
INFLAMMATORY BOWEL DISEASES, 2007, 13 (09) : 1188 - 1189
[39] Anti-Tumor Necrosis Factor Therapy to Prevent Crohn's Disease Recurrence After Surgery
Herfarth, Hans H.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (09) : 1503 - 1506
[40] A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn's Disease
Nie, Kai
Zhang, Chao
Deng, Minzi
Luo, Weiwei
Ma, Kejia
Xu, Jiahao
Wu, Xing
Yang, Yuanyuan
Wang, Xiaoyan
FRONTIERS IN PHARMACOLOGY, 2022, 13

← 1 2 3 4 5 →